Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) has announced positive initial results from its research product with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
As quoted in the press release:
The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-inflammatory preclinical model. Initial results successfully demonstrated a stable formulation of the TNN-CHT composites and synthetic CBD (TNN-CHT/CBD). The TNN-CHT/CBD formulation shown to attenuate LPS-induced macrophage activation in a dose-response manner, showing a reduction for inducible nitric oxide synthase (iNOS), as well as an increase on intracellular production of tumor necrosis factor alpha (TNF-a) as the concentration of CBD is increased. In summary, the TNN-CHT/CBD formulation exhibits anti-inflammatory properties and suggested that the TNN-CHT composites have anti-inflammatory activity that may complement CBD. The project is ongoing with further optimization of the TNN-CHT/CBD formulation and final results will be made available before the end of the year.
“This is a significant development milestone as we have successfully demonstrated that the delivery technology in combination with cannabidiol is able to effectively reduce inflammation offering a novel and potentially effective therapeutic option for a broad range of indications that would benefit from cannabinoid therapies,” said Dr. Jess D. Reed, Professor of Animal Nutrition at the University of Wisconsin-Madison. “We are optimizing the formulation for permeation and inflammatory studies in order to further validate the potential of the cannabinoid delivery technology.”
“I am pleased with these initial results as it has successfully demonstrated that the cannabinoid delivery technology has shown a positive effect in reducing inflammation and has the potential to be a unique cannabinoid delivery technology offering novel solutions for the medical cannabis and pharmaceutical sectors,” said Craig Leon, Chief Executive Officer of Revive.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact email@example.com, or